CFH and chronic kidney disease: At the last follow-up evaluation, 33% had no sequelae (n=2; one of these patients had anti-factor H antibodies and eculizumab was not administered), 67% had HBP (n=4), 33% had CKD (n=2), and none of the patients underwent KT.